Oncolytics Biotech Inc T.ONC

City of Hope Developes CAR-T Cell Therapy in Ovarian Cancer

[Noteable]

"City of Hope's research helped develop CAR T cell therapies for blood cancers, and these patients are now seeing long-term benefits from the therapy, but we can't stop there," said Saul Priceman, Ph.D., associate professor in the Department of Hematology & Hematopoietic Cell Transplantation and associate director of Translational Sciences & Technologies in the T Cell Therapeutics Research Laboratory at City of Hope. "The next frontier is solid tumors, and City of Hope is taking on that challenge."

Developing a CAR T cell therapy for solid tumors is particularly challenging because the therapy needs to first reach the solid tumor and then survive in a harsh microenvironment that is filled with cancer cells and other cells that prevent attack by the CAR T cells.

Priceman and his team also found that by adding the cytokine Interleukin-12 (IL-12), a protein that sends signals to the immune system, to the CAR T cell therapy.

ONCYs pelareorep is able to convert a harsh microenvironment that is filled with cancer cells and other cells that prevent attack by the CAR T cells.

https://www.biospace.com/article/releases/city-of-hope-researchers-develop-a-car-t-cell-therapy-for-advanced-ovarian-cancer/

[jimsenior]

@Noteable. Very Interesting. For information only. City of Hope Medical Center is a collaborator on NCT03605719. That is the MM trial with pela, carfilzomib, opdivo et al. Hofmeister. News on the CAR T front woud be nice. I still think pela is very much in the hunt, but there is a lot happening on the oncology front, and we do not want to be left behind. GO

[jimsenior]

To Anyone. I do not listen to calls any more. If something was said about MM yesterday, please relay the info.

[JohnnyYeg]

Basically don't expect any updates on GOBLET until 2025. As for mBC? Your guess is as good as anyones.

[fox7mf]

Yeah, the call has caused great concern amongst some of those who listened. Some have gleaned from MC's comments that PDAC won't have a partner (other than PanCan) and that no business development deals are on the horizon. MBC may or may not have been relegated to the backburner. Matt needs to clarify on Monday, and explain just what he meant when he said back in November that Oncy was

[Lesalpes29]

Thank you Fox...confiance effritee today. Was a believer with Parsons and Rigby on the BOD. Now.I'm not sure.

[fox7mf]

So Noteable, some longs are still digesting the chat. What's your take on mBC? Did we waste 5 years, and at the same time fall behind the likes of Enherto? Did MC say as much? Is mBC an afterthought now?

[Buckhenry]

Unnoteable has been posting garbage for years and well... we see what the stock has done. You folks are dumber  than a box of rocks listening to the dreamers on here. But as PT Barnum  said  100 years ago. A sucker is born every minute. 

[Noteable]

What's my take on mBC?  Well what we can take away is that from the BRACELET-1 study is that in comparing Cohort 1 vs Cohort 2 vv Cohort 3 of the HR+/HER2 - Phase 2 mBC study Cohort 2 comprised of the Pelareorep  + paclitaxel combination is responsive ito the treatment of mBC as compared to paclitaxel alone or in combination with Bavencio. Bracelet-1 has demonstrated that pelareorep

[Noteable]

And now that the FDA has enhanced their accelerated approval process, an accelerated approval of pelareorep in combination with paclitaxel could happen soon after ONCY files the company's Phase 3 mBC study, particularly since patients from ONCY's IND-213 and BRACELET-1 could be included in the number count in an adaptive Phase 3 study,    I would anticipate.

[fox7mf]

I agree wholeheartedly Note. However, did you not get the impression from the chat that it's peddle to the metal on PDAC and perhaps CRC, whereas mBC has been shuffled to 3rd string? MC needs to lend clarification on Mon.